Synovus Financial Corp Editas Medicine, Inc. Transaction History

Synovus Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 09, 2020	SELL	$28.06 - $37.16 $5,836 - $7,729	-208 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$18.5 - $34.34 $1,850 - $3,434	100 Added 92.59%	208 $6,000
Q1 2020 Apr 24, 2020	BUY	$14.88 - $32.78 $595 - $1,311	40 Added 58.82%	108 $2,000
Q4 2019 Feb 06, 2020	BUY	$19.49 - $32.63 $1,169 - $1,957	60 Added 750.0%	68 $2,000
Q2 2018 Aug 01, 2018	BUY	$31.4 - $41.01 $251 - $328	8 New	8 $0

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $104M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Synovus Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Synovus Financial Corp with notifications on news.